New IL-23-targeted biologic approved in Canada for Tx of plaque psoriasis
Guselkumab, a biologic therapy that is part of a new class of agents targeting interleukin (IL)-23 without blocking IL-12, was approved...
top of page
it's where dermatology lives
Featured Posts
bottom of page